

# Anthony Serracino-Inglott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7753522/publications.pdf>

Version: 2024-02-01

46  
papers

322  
citations

1306789

7  
h-index

887659

17  
g-index

46  
all docs

46  
docs citations

46  
times ranked

401  
citing authors

#	ARTICLE	IF	CITATIONS
1	A simple HPLC-UV method for the determination of ciprofloxacin in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 989, 80-85.	1.2	82
2	Consumer perception of the community pharmacist and community pharmacy services in Malta. <i>Journal of Pharmaceutical Health Services Research</i> , 2010, 1, 189-194.	0.3	53
3	European Union pharmacovigilance capabilities: potential for the new legislation. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 120-140.	1.0	22
4	Treatment of Leber's hereditary optic neuropathy: An overview of recent developments. <i>European Journal of Ophthalmology</i> , 2020, 30, 1220-1227.	0.7	20
5	Pharmaceuticals and the environment. <i>Early Human Development</i> , 2021, 155, 105218.	0.8	16
6	Pharmacist-led medicine use review in community pharmacy for patients on warfarin. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 741-750.	1.0	10
7	Time and motion study for pharmacists' activities in a geriatric hospital. <i>International Journal of Pharmacy Practice</i> , 2010, 17, 373-376.	0.3	9
8	Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 333-345.	0.5	8
9	Factors Affecting Penetration of Ciprofloxacin in Lower Extremity Ischemic Tissues. <i>International Journal of Lower Extremity Wounds</i> , 2016, 15, 126-131.	0.6	8
10	Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. <i>AAPS PharmSciTech</i> , 2018, 19, 489-511.	1.5	8
11	Clinical pharmacy education and practice evolution in Malta. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 973.	0.5	8
12	Development of protocols for the provision of headache and back-pain treatments in Maltese community pharmacies. <i>International Journal of Pharmacy Practice</i> , 2010, 17, 269-274.	0.3	7
13	Standardising pharmacist patient-profiling activities in a rehabilitation hospital in Malta. <i>European Journal of Hospital Pharmacy</i> , 2014, 21, 49-53.	0.5	5
14	Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 815-826.	1.0	5
15	Point-of-Care Testing for Urine Analysis and Microalbuminuria for Diabetic Patient Management. <i>Point of Care</i> , 2015, 14, 71-72.	0.5	4
16	Opinions of Maltese doctors and pharmacists on medication errors. <i>International Journal of Risk and Safety in Medicine</i> , 2017, 29, 81-99.	0.3	4
17	The shift from class-based to online learning during COVID-19: A student and academic perception. <i>Pharmacy Education</i> , 2020, 20, 290-296.	0.2	4
18	Improving the data quality of spontaneous ADR reports: a practical example from Malta. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 253-268.	1.0	4

#	ARTICLE	IF	CITATIONS
19	The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. <i>Drug Discovery Today</i> , 2022, , .	3.2	4
20	Development of external methods to evaluate the quality of pharmacy services offered by community pharmacists. <i>Quality Assurance Journal</i> , 2003, 7, 248-257.	0.1	3
21	Compilation of a herbal medicine formulary for herbal substances in Malta and its usefulness amongst healthcare professionals. <i>Journal of Young Pharmacists</i> , 2013, 5, 22-25.	0.1	3
22	A review of the National pharmacovigilance system in Malta – implementing and operating a pharmacovigilance management system. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 65-76.	1.0	3
23	Changing paradigms in bioequivalence trials submitted to the EMA for evaluation – A clinical and regulatory perspective. <i>Saudi Pharmaceutical Journal</i> , 2017, 25, 280-289.	1.2	3
24	Clinical pharmacist implementation of a medication assessment tool for long-term management of atrial fibrillation in older persons. <i>Pharmacy Practice</i> , 2019, 17, 1349.	0.8	3
25	Exploring views of pharmacists on antibacterial prescribing: a Maltese perspective. <i>International Journal of Pharmacy Practice</i> , 2019, 27, 256-263.	0.3	3
26	Pharmacist interventions in non-prescription medicine use. <i>Journal of Pharmaceutical Health Services Research</i> , 2014, 5, 55-59.	0.3	2
27	Proposing a Framework for International Normalized Ratio Testing and Anticoagulation Management in Community Pharmacies. <i>Point of Care</i> , 2014, 13, 125-127.	0.5	2
28	Practices and perceptions of medical practitioners on potential antibiotic prescribing by pharmacists. <i>Journal of Pharmaceutical Health Services Research</i> , 2016, 7, 157-164.	0.3	2
29	Design and application of a medication assessment tool for secondary prevention of stroke. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 1008-1012.	1.0	2
30	Assessing appropriateness of drug therapy in older persons: Development and application of a medication assessment tool for long-term management of atrial fibrillation. <i>Pharmacy Practice</i> , 2017, 15, 1021-1021.	0.8	2
31	Preparing for pharmacist prescribing in Maltese hospitals. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 237-243.	0.3	2
32	Optimising bench science to withstand regulatory scrutiny. <i>Pharmacological Research</i> , 2019, 139, 491-493.	3.1	2
33	Pharmacist and physician perception of pharmacogenetic testing. <i>International Journal of Pharmacy Practice</i> , 2022, 30, 188-191.	0.3	2
34	Comment On: –EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars– <i>Drug Safety</i> , 2014, 37, 123-124.	1.4	1
35	Pharmacist intervention in a psychiatric setting. <i>European Journal of Hospital Pharmacy</i> , 2015, 22, 280-284.	0.5	1
36	A multi-technique analytical approach for impurity profiling during synthesis: The case of difluprednate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 190, 113483.	1.4	1

#	ARTICLE	IF	CITATIONS
37	How to think like Francke for a global vision in challenging times. American Journal of Health-System Pharmacy, 2021, 78, 606-612.	0.5	1
38	Development of protocols for the provision of headache and back-pain treatments in Maltese community pharmacies. International Journal of Pharmacy Practice, 2009, 17, 269-274.	0.3	1
39	Time and motion study for pharmacists' activities in a geriatric hospital. International Journal of Pharmacy Practice, 2009, 17, 373-376.	0.3	1
40	QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?. Current Medical Research and Opinion, 0, , 1-30.	0.9	1
41	Perceptions of a newsletter for community pharmacists. Journal of Pharmaceutical Health Services Research, 2013, 4, 101-103.	0.3	0
42	Development and evaluation of a Drug Information Bulletin. Journal of Pharmaceutical Health Services Research, 2014, 5, 81-88.	0.3	0
43	Pharmaceutical issues during the review of European Marketing Authorisation Applications in Malta. Pharmaceutical Development and Technology, 2018, 23, 561-572.	1.1	0
44	Clinical pharmacist implementation of a medication assessment tool for secondary prevention of stroke in older persons. Journal of Pharmaceutical Health Services Research, 2018, 9, 207-214.	0.3	0
45	Public perception of generic medicines in Malta. Journal of Pharmaceutical Health Services Research, 2020, 11, 295-298.	0.3	0
46	Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia. Drug Discovery Today, 2022, , .	3.2	0